Bristol Myers Squibb AI Access Timeline
Reviewed Strategic Signal records on Bristol Myers Squibb’s AI access relationships, rights, and disclosed economics.
These selected timelines include reviewed registry records that explicitly name each organization in a participant field. A product, affiliate, or parent name alone does not establish participation. Coverage reflects Strategic Signal’s research sample. Records are ordered by original announcement date. A record may reflect later amendments or evidence updates.
Oct 23, 2026 · Data-rights qualified
Tempus AI → Bristol Myers Squibb
Certain multimodal records from Tempus AI's de-identified oncology dataset, licensed to Bristol Myers Squibb for analysis and use with Pathos Foundry in therapeutic development.
Bristol Myers Squibb role · AI recipient · Strategic buyer or operator
- Provider / asset owner — Tempus AI
- AI recipient — Bristol Myers Squibb
- Strategic buyer or operator — Bristol Myers Squibb
Recorded status · agreement disclosed active term. Last reviewed Oct 27, 2026.
Access · corpus delivery. Training rights · not disclosed.
Disclosed economics · $137.5 million in aggregate fixed payments, invoiced quarterly over the term; realized cash receipts are not verified. Scope · Contractual consideration covers the oncology data license, Lens access, and related analysis and research services; no allocation among those components is disclosed.
Evidence
Oct 1, 2025 · Data-rights qualified
AbbVie → AISB Federated OpenFold3 Initiative
Proprietary experimentally determined protein–small molecule structures supplied for federated fine-tuning. This observation records the October 2025 consortium expansion.
Bristol Myers Squibb role · Provider / asset owner
- Provider / asset owner — AbbVie, Johnson & Johnson, Bristol Myers Squibb, Takeda, Astex Pharmaceuticals
- AI recipient — AISB Federated OpenFold3 Initiative, AlQuraishi Lab, Apheris
- Strategic buyer or operator — AISB Federated OpenFold3 Initiative, AlQuraishi Lab, Apheris
Recorded status · active. Last reviewed Sep 16, 2026.
Access · training, post training. Training rights · permitted.
Disclosed economics · No data-specific consideration disclosed. Scope · not disclosed